Geron Corporation (GERN) Licenses Nuclear Transfer Technology To Revivicor, Inc.
10/19/2005 5:12:13 PM
Geron Corporation (Nasdaq:GERN) announced today that it has entered into two non-exclusive license agreements with Revivicor, Inc., under which Revivicor is granted rights to use Geron's nuclear transfer technology for animal cloning. The first license grants Revivicor the right to use the technology to produce animal organs and tissues for xenotransplantation. Xenotransplantion, which involves the use of animal organs and tissues for transplant into humans, offers the potential to address critical shortages of donated human tissues and fulfill currently unmet clinical needs. The second license grants Revivicor the right to use the technology to produce human proteins from the blood of animals for pharmaceutical uses, such as polyclonal antibodies for vaccine use.
comments powered by